Huntington's disease (Q28284355)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

review article

1 reference

title

Huntington's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Francis O Walker

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

9557

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

218-228

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Objective assessment of progression in Huntington's disease: a 3-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Transcriptional dysregulation in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntington's disease genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Awareness of involuntary movements in Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Critical periods of suicide risk in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Suicide in Hungarian Huntington's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Suicide risk in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

High suicidal ideation in persons testing for Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

1 reference

7 January 2021

Huntington's disease in Venezuela: neurologic features and functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntington's disease: clinical correlates of disability and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Coordination of prehensile forces during precision grip in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntington's Disease-like 2 (HDL2) in North America and Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

SCA17 homozygote showing Huntington's disease-like phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Family history and DNA analysis in patients with suspected Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

1 reference

7 January 2021

Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Pyramidal cell loss in motor cortices in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Reduced Purkinje cell density in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Bicaudate diameter?the most specific and simple CT parameter in the diagnosis of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Onset and rate of striatal atrophy in preclinical Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Reduced penetrance of the Huntington's disease mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Familial influence on age of onset among siblings with Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Evidence for the GluR6 gene associated with younger onset age of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Different phenotypic expression in monozygotic twins with Huntington disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Homozygotes for Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Testing for Huntington's disease with support for all parties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Guidelines for the molecular genetics predictive test in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Genetic testing and Huntington's disease: issues of employment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

New tools for preimplantation genetic diagnosis of Huntington's disease and their clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntington's disease: prenatal screening for late onset disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Predictive testing for Huntington's disease: a universal model?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

The large Huntington's disease family of Tasmania.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntington's disease in black kindreds in South Carolina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Polyglutamine tract expansion of the androgen receptor in a motoneuronal model of spinal and bulbar muscular atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Spinocerebellar ataxia type 6. Frequency of the mutation and genotype-phenotype correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

SCA-12: Tremor with cerebellar and cortical atrophy is associated with a CAG repeat expansion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

CAG mutation effect on rate of progression in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Differences in duration of Huntington's disease based on age at onset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Nuclear targeting of mutant Huntingtin increases toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

A cellular model that recapitulates major pathogenic steps of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Apoptosis in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Axonal transport failure in neurodegenerative disorders: the case of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Fly models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Behavior in Huntington's Disease: Dissociating Cognition-Based and Mood-Based Changes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Neuropsychiatric aspects of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Weight loss in early stage of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Gene expression in Huntington's disease skeletal muscle: a potential biomarker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960111-1

1 reference

7 January 2021

10.1016/S0140-6736(07)60111-1

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

887308

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17240289%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

887308

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

887308